Individualizing the initial prescription and level of support
We return to Miranda, a 52 yo woman with a history of recurrent major depressive disorder (MDD) who is severely depressed. In part 1 of this PsychSnap, we clarified her prior medication trials of fluoxetine, sertraline, bupropion and escitalopram. For each medication, we discussed the maximum dose, how long she took it, what it helped with (if anything), what side effects it caused, and why it was stopped.
After learning her medication history, you recommended that Miranda restart fluoxetine. Fluoxetine helped her depression in her early 20s without side effects. She took fluoxetine 40mg daily for 8 months and stopped it at psychiatrist’s recommendation when her depression was in remission for >6 months.
Individualizing the initial prescription and level of support
If we prescribe an antidepressant, what dose do we start and how do we increase it? A slower antidepressant up-titration may reduce side effects and improve initial adherence, but it may also delay clinical response (Torta 2012).
Most people will benefit from what I call the “standard start,” with an initial target dose of the lowest effective dose. For sertraline, for example, my standard start would be: sertraline 50 mg tabs, Sig: Take ½ tab (25mg) PO daily for 6 days, then 1 tab (50mg) PO daily. It’s a minor thing, but if there is only 1 dose change in an initial prescription that involves cutting pills, I increase the dose after 6 days (rather than 7 days) so the patient doesn’t end up with a half-pill left in their bottle.
Starting lower to improve tolerability
On the resources page of the PsychSnaps website is a reference table of standard starts, low-dose starts, and very low-dose starts for commonly used antidepressants. I’d recommend looking at it now, before continuing with the text.
For a low-dose start, we start at a lower dose but aim for the same initial target dose. If patients don’t tolerate low dose starts due to side effects, you can also try a very-low dose start, using liquid formulations of the SSRIs or lower dosages of pills for bupropion or mirtazapine.
| Start at a lower dose Prioritizes tolerability over clinical efficacy. Consider pairing with extra support. Example: sertraline 25mg tabs; Sig ½ tab (12.5mg) PO daily for 1 week, then 1 tab (25mg) PO daily for 1 week, then 2 tabs (50mg) PO daily —– For patients who: Have a history of side effects from other antidepressants Are likely to stop a medication if they experience any side effect Have a high level of anxiety about starting a medication Have recurrent panic attacks Are older adults | Don’t start yet For patients who: Think the medication is likely to harm them (avoid nocebo) Have low motivation for starting a medication (see part 1 of this PsychSnap) If you don’t have time today to provide “standard support” (see below) |
Aiming for a higher target dose to reach clinical efficacy faster
We may want to titrate antidepressants to a higher target dose initially if we expect a patient to need a higher dose due to their clinical history, or if clinical efficacy (rather than tolerability) is our main focus. Titration schedules to a moderate target dose from a standard start are also included in the table Depression: Dosing and Titration of Antidepressants on the resources page of the PsychSnaps website.
| Aim for a higher target dose Prioritizes clinical efficacy over risk of side effects. Begin with the “standard start” but keep increasing the dose weekly to get the patient to a higher dose faster. Example: sertraline 50 mg tabs, Sig: ½ tab (25mg) PO daily for 1 week, then 1 tab (50mg) PO daily for 1 week, then 2 tabs (100mg) PO daily —– For patients who: Are restarting a medication that was tolerable to them and helped them at a specific dose – aim for the prior effective dose to get there sooner. Have severe depressive illness – aim for moderate dose Have OCD – aim for moderate dose Have had no response to 1 or more adequate trials of an antidepressant this episode and have tolerated medications well – aim for moderate dose |
The prescription is never the entirety of your treatment.
In randomized controlled trials, two-thirds to three-quarters of the positive outcomes observed with antidepressant treatment of depression may be attributed to non-specific and placebo effects. In other words, most people in an antidepressant trial for MDD who receive a placebo pill improve significantly, reflecting some combination of the natural history of mood disorders and the effect of interpersonal support and increased hope derived from participation in a treatment study (Bschor 2024).
How do we individualize the level of interpersonal support to maximize the non-specific support from treatment and improve patient adherence with medication? We know that 42% of patients who start an antidepressant discontinue it within the first month of treatment (Olfson 2006). It is hard to take medication daily when there may be immediate side effects but the clinical benefits are delayed for weeks. Every patient getting a new antidepressant prescription should receive “standard support.” Some should also be offered extra support.
| Standard support for everyone | Extra support for people with significant anxiety or a history of stopping antidepressants within days |
| -Explain the rationale for the medication. “Your depression is in the moderate-to-severe range. I think you might benefit from an antidepressant medication like [sertraline].” –Provide patient with verbal and written instructions, including the expectation of delayed efficacy and anticipatory guidance around potential early and chronic side effects. -Express hope that the medication may be helpful. “I know it’s a big step to decide to take an antidepressant. You’ve been suffering with this depression for almost 4 months. I’ve seen many patients with symptoms like yours improve with an antidepressant. I’m hopeful that you’ll be starting to feel better the next time that I see you.” -Ask “What questions do you have?” -Schedule follow-up in 4-6 weeks. | -Additional brief check-in after 1 week Did you pick up the medication? Did you start taking it? How are you taking it? How is it going? What side effects do you have? What concerns do you have at this time? Review that clinical benefit is not expected for another 1-3 weeks. Review planned dose changes. Review the follow-up plan. -Schedule follow-up in 2-4 weeks. |
Very anxious patients who seem motivated to take medication but are too anxious to get started may benefit from the extra support of taking the first pill at the beginning of an appointment with you or with a therapist.Returning to Miranda: You recommend starting fluoxetine with a plan to titrate to a target dose of 40mg daily, because that’s the dose that was previously effective for her. This is a standard start to a moderate initial target dose. Specifically, you prescribe fluoxetine 20mg tabs, with a plan to start ½ tab PO qAM for 1 week, then 1 tab PO qAM for 1 week, then 2 tabs (40mg) PO qAM.
You also use a drug-interaction checker to confirm that CYP-P450 inhibition by fluoxetine will not cause issues with her other medications.
Miranda is motivated to start taking medication and hasn’t had previous trouble with short-term adherence with antidepressants. You include standard-support with your prescription and schedule a follow-up in 4-6 weeks.
Stay tuned for Part 3 of this PsychSnap: individualizing future dose changes.
Key Points
- Starting at a lower dose prioritizes tolerability over clinical efficacy. Consider pairing low-dose starts with extra support, particularly for anxious patients.
- Aim for a higher initial target dose of an antidepressant in patients who have previously benefited from a higher dose.
- Aiming for a moderate target dose in patients with severe depression prioritizes clinical efficacy and shortens the duration of an adequate antidepressant trial from 10 to 6 weeks.
Related PsychSnaps:
“How do you individualize antidepressant prescribing? (part 1). Taking a psychotropic medication history and assessing current motivation for treatment.” Emma Samelson-Jones, June, 2026.
“How do you choose an antidepressant?” Emma Samelson-Jones, May 2023.
References:
Bschor, Tom, et al. “Differential outcomes of placebo treatment across 9 psychiatric disorders: a systematic review and meta-analysis.” JAMA psychiatry 81.8 (2024).
Carlat, Daniel and Talia Puzantian, “Medication fact book for psychiatric practice: sixth edition.” Carlat Publishing, 2022.
Drug Approvals and Datatbases Development and Approval. Drugs@ FDA. Website: www.accessdata.fda.gov/scripts/cder/daf/ accessed 6/10/2026.
Olfson, Mark, et al. “Continuity of antidepressant treatment for adults with depression in the United States.” American Journal of psychiatry 163.1 (2006): 101-108.
Stahl, Stephen M. Stahl’s essential psychopharmacology: neuroscientific basis and practical applications. Cambridge university press, 2021.
Torta, Riccardo GV. “Antidepressant up-titration: pharmacological and psychological considerations.” Expert opinion on drug safety 11.5 (2012): 685-688.
Send a Comment